VEGFC and hepatocellular carcinoma: Angiogenesis Liver CancEr 2 (ALICE-2), a retrospective multicenter study of 210 patients with advanced HCC, recently identified a panel of H1F-1α, VEGF-A, VEGF-C, VEGFR-1, and VEGFR-3 variants to be associated with better response to sorafenib treatment [29].